Eye­ing Eylea's $5B sales, No­var­tis touts sol­id 12-week dos­ing da­ta for its ri­val RTH258

No­var­tis is rolling out new da­ta that build on its case for the com­pa­ny’s block­buster hope­ful RTH258, an in­ves­ti­ga­tion­al ther­a­py that might carve away a con­sid­er­able chunk of Re­gen­eron’s $5 bil­lion Eylea fran­chise if ap­proved.

The new da­ta, which came from a sec­ondary analy­sis of two Phase III tri­als, show a com­pelling case for the drug as a treat­ment for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion. The drug al­ready showed im­pres­sive suc­cess in those tri­als last fall, when it per­formed well in a head-to-head com­par­i­son to Eylea. Sim­ply put, No­var­tis’ CEO Vas Narasimhan said the drug was “con­sis­tent­ly su­pe­ri­or” to its Re­gen­eron ri­val.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER